ReviewMaedica2026
Diagnostic and Clinical Significance of the Special AT-Rich Sequence-Binding Protein 2 Deregulation in Gastrointestinal Malignancies.
Review in Maedica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gastrointestinal malignancies (GIs) - especially the colon adenocarcinoma (CAD) - represent the third leading cause of cancer-related morbidity and mortality, respectively. The development and progression of CAD is a multistep procedure in which a variety of deregulated molecules are implicated. Among them, the special AT-rich sequence-binding protein 2 (SATB2, gene locus: 2q33.1) seems to be a reliable marker for differential diagnosis and prognosis in patients suffering from GIs. Objective: The purpose of the current clinic-molecular review was to describe the role of the SATB2 protein in normal cell homeostasis and activity of epithelial cells and also to investigate the impact of its deregulation on GI and especially CAD patients. Material and method: A systematic review of the literature was implemented based on the international PubMed database. Publications were evaluated at the basis of scientific importance and historical value regarding the SATB2 identification, nature, function and deregulation. The following keywords were used: SATB2, colon, carcinoma, transcription, DNA-binding. Fifty (n=50) important papers were selected for providing well-documented knowledge for the marker's behavior in non- and neoplastic disorders, also focused on GIs and CAD malignancies (CADs). Results: The majority of the examined original research studies reported a bi-phasic (overexpression/loss of expression) SATB2 protein pattern in GIs and specifically CADs. Additionally, they suggest that SATB2 should be a part of an immunohistochemical (IHC) panel - which also includes markers such as cytokeratins and transcriptional factors (caudal type homeobox 2-CDX2) - for implementing an accurate IHC-based diagnosis in primary and metastatic malignant tumors with GI origin. Conclusions: SATB2 is a reliable and sensitive protein marker for differential diagnosis regarding GIs, including CADs. SATB2 gene silencing that leads to low or complete loss of its expression seems to be associated with an aggressive phenotype in CADs (advanced stage, increased metastatic potential, short survival rates).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.